L-689,660, a novel cholinomimetic with functional selectivity for M1 and M3 muscarinic receptors
- PMID: 1422595
- PMCID: PMC1907894
- DOI: 10.1111/j.1476-5381.1992.tb12773.x
L-689,660, a novel cholinomimetic with functional selectivity for M1 and M3 muscarinic receptors
Abstract
1. L-689,660, 1-azabicyclo[2.2.2]octane, 3-(6-chloropyrazinyl)maleate, a novel cholinomimetic, demonstrated high affinity binding (pKD (apparent) 7.42) at rat cerebral cortex muscarinic receptors. L-689,660 had a low ratio (34) of pKD (apparent) values for the displacement of binding of the antagonist ([3H]-N-methylscopolamine ([3H]-NMS) compared with the displacement of the agonist [3H]-oxotremorine-M ([3H]-Oxo-M), in rat cerebral cortex. Low NMS/Oxo-M ratios have been shown previously to be a characteristic of compounds that are low efficacy partial agonists with respect to stimulation of phosphatidyl inositol turnover in the cerebral cortex. 2. L-689,660 showed no muscarinic receptor subtype selectivity in radioligand binding assays but showed functional selectivity in pharmacological assays. At M1 muscarinic receptors in the rat superior cervical ganglion, L-689,660 was a potent (pEC50 7.3 +/- 0.2) full agonist in comparison with (+/-)-muscarine. At M3 receptors in the guinea-pig ileum myenteric plexus-longitudinal muscle or in trachea, L-689,660 was again a potent agonist (pEC50 7.5 +/- 0.2 and 7.7 +/- 0.3 respectively) but had a lower maximum response than carbachol. In contrast L-689,660 was an antagonist at M2 receptors in guinea-pig atria (pA2 7.2 (95% confidence limits 7, 7.4)) and at muscarinic autoreceptors in rat hippocampal slices. 3. The putative M1-selective muscarinic agonist, AF102B (cis-2-methylspiro-(1,3-oxathiolane 5,3')-quinuclidine hydrochloride) was found to have a profile similar to L-689,660 but had up to 100 times less affinity in binding and functional assays.RS-86 (2-ethyl-8-methyl-2,8-diazospiro[4,5]decan 1,3-dionehydrochloride) also had lower affinity than L-689,660, and had no binding selectivity for muscarinic receptor subtypes. RS-86 had a higher NMS/Oxo-M ratio than L-689,660 and was a full agonist at MI,M2 and M3 receptors in the functional pharmacological assays.4. The functional selectivity of L-689,660 in muscarinic pharmacological assays is consistent with the effects of a low efficacy partial agonist in tissues with different effective receptor reserves.
Similar articles
-
Pharmacological characterization of the novel cholinomimetic L-689,660 at cloned and native brain muscarinic receptors.J Pharmacol Exp Ther. 1993 Dec;267(3):1478-83. J Pharmacol Exp Ther. 1993. PMID: 8263809
-
The design of novel muscarinic partial agonists that have functional selectivity in pharmacological preparations in vitro and reduced side-effect profile in vivo.Life Sci. 1993;52(5-6):489-95. doi: 10.1016/0024-3205(93)90306-n. Life Sci. 1993. PMID: 8441329 Review.
-
(+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3')quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease.J Pharmacol Exp Ther. 1991 Apr;257(1):392-403. J Pharmacol Exp Ther. 1991. PMID: 2019998
-
Affinities of muscarinic drugs for [3H]N-methylscopolamine (NMS) and [3H]oxotremorine (OXO) binding to a mixture of M1-M4 muscarinic receptors: use of NMS/OXO-M ratios to group compounds into potential agonist, partial agonist, and antagonist classes.Neurochem Res. 1995 Jun;20(6):669-74. doi: 10.1007/BF01705534. Neurochem Res. 1995. PMID: 7566362
-
Discovery & development of selective M3 antagonists for clinical use.Life Sci. 1997;60(13-14):1053-60. doi: 10.1016/s0024-3205(97)00047-7. Life Sci. 1997. PMID: 9121347 Review.
Cited by
-
A comparison of the effects of the novel muscarinic receptor agonists L-689,660 and AF102B in tests of reference and working memory.Psychopharmacology (Berl). 1994 Jan;113(3-4):361-8. doi: 10.1007/BF02245210. Psychopharmacology (Berl). 1994. PMID: 7862846
-
SR 46559A: a novel and potent muscarinic compound with no cholinergic syndrome.Psychopharmacology (Berl). 1993;112(2-3):219-27. doi: 10.1007/BF02244914. Psychopharmacology (Berl). 1993. PMID: 7871023
-
Potential Role for Combined Subtype-Selective Targeting of M1 and M3 Muscarinic Receptors in Gastrointestinal and Liver Diseases.Front Pharmacol. 2021 Nov 4;12:786105. doi: 10.3389/fphar.2021.786105. eCollection 2021. Front Pharmacol. 2021. PMID: 34803723 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources